Clinical Trials Directory

Trials / Sponsors / Cognition Therapeutics

Cognition Therapeutics

Industry · 13 registered clinical trials.

StatusTrialPhaseStarted
Active Not RecruitingA Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Early Alzheimer's Disease
Phase 22023-06-28
TerminatedStudy to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondar
Age-Related Macular Degeneration
Phase 22023-06-16
CompletedStudy to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia W
Dementia With Lewy Bodies
Phase 22022-05-19
CompletedStudy to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers
Alzheimer Disease
Phase 12022-02-15
CompletedStudy to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjec
Alzheimer Disease
Phase 12021-12-31
CompletedPilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
Alzheimer Disease
Phase 22020-07-09
CompletedA Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Mild to Moderate Alzheimer's Disease
Phase 22018-10-10
CompletedStudy to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects Wi
Alzheimer Disease
Phase 12018-05-30
CompletedEffect of CT1812 Treatment on Brain Synaptic Density
Alzheimer Disease
Phase 1 / Phase 22018-03-28
CompletedDrug Interaction Study of CT1812 in Healthy Volunteers
Healthy Volunteers
Phase 12016-11-10
CompletedClinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
Phase 1 / Phase 22016-09-01
CompletedAscending Dose Study of CT1812 in Healthy Volunteers
Cognitive Impairment
Phase 12015-09-01
No Longer AvailableExpanded Access Program for CT1812 (Zervimesine)
Dementia With Lewy Bodies
——